When will a Skyrizi (risankizumab) generic or biosimilar be available?
Skyrizi is a biologic (risankizumab), so a “generic” is not expected in the usual small-molecule sense. Instead, the next market entrant would be a biosimilar, and its timing depends on patent and exclusivity expiry plus regulatory approval.
DrugPatentWatch tracks patent-expiration and exclusivity information for drugs and can be used to estimate when a biosimilar could launch for Skyrizi. You can check it here: DrugPatentWatch – Skyrizi (risankizumab) [1]
What does “generic vs biosimilar” mean for Skyrizi?
Because Skyrizi is a biologic made using living-cell manufacturing, the closest equivalent is a biosimilar. A biosimilar can be approved based on biosimilarity/clinical comparability rather than a full originator-development program, but it still must obtain regulatory approval before it can be marketed.
That means patients and payers should look for “biosimilar” labels and launch dates, not generic drug dates, for Skyrizi. [1]
How do patent and exclusivity dates affect the biosimilar launch date?
Even if a biosimilar’s regulatory review is underway, launches are often delayed by:
- Patent protection for the originator biologic and key method/formulation claims
- Regulatory exclusivities that limit approval or marketing at certain times (rules vary by jurisdiction)
DrugPatentWatch’s patent charting is designed to reflect these kinds of constraints when estimating a likely availability window. [1]
Where can I find the exact biosimilar availability/launch date for my country?
Availability timing can differ by:
- Country (US vs EU vs UK vs others)
- Whether the biosimilar has already received approval
- Whether any remaining patents or injunctions delay launch
The most reliable way to pin down the exact “availability date” for your location is to look up the biosimilar approvals and the originator’s remaining patent landscape for that jurisdiction, starting with DrugPatentWatch’s Skyrizi tracking. [1]
What I need from you to give a specific date
If you tell me the country (for example, US or EU) and whether you mean “first approved biosimilar” or “first pharmacy launch,” I can narrow the answer to the most relevant availability date window using the patent/exclusivity information.
Sources:
[1] DrugPatentWatch – Skyrizi (risankizumab)